Cardiac Effects of Experimental Intravenous Bone Marrow Cell Transplantation after Myocardial Infarction

Holinski, Sebastian; Heinze, Georg; Knebel, Fabian; Borges, Adrian C.; Baumann, Gert; Rudolph, Birgit; Konertz, Wolfgang

doi:10.5761/atcs.oa.11.01797

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first is that no information was found on whether the patients received HF treatment, and, if so, how regular that treatment was. The second reason is that when the possibility of cardiac regeneration due to HSCT is emphasized, the probability of stem cells passing through the pulmonary artery and capillaries without any damage after transplantation is low [17].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Cardiac Parameters in Bone Marrow Transplant Patients: Effect of Pulmonary Artery Pressure on Survival

Ozdover

Gündeş

Kırık

et al. 2019

Tjh

View full text Add to dashboard Cite

Objective: Hematopoietic stem cell transplantation (HSCT) is a choice of treatment for malignant and non-malignant diseases. After HSCT, some complications may develop in patients. Cardiac complications are particularly important. The aim of this study was to investigate whether systolic pulmonary artery pressure (PAP) is a marker for overall survival (OS) in HSCT patients. Materials and Methods: In our study, 428 HSCT patients were evaluated. Ejection fraction (EF) and PAP values were investigated during symptom-oriented echocardiography in the pre-HSCT and post-HSCT periods. Results: Pre-HSCT EF values were similar between the groups. In patients with autologous HSCT (auto-HSCT) (PAP >25 mmHg), it was found that the 5-year mortality rate was 48.6%, while in the other group (PAP <25 mmHg) the 5-year mortality was 25.5%. There was a significant association between 5-year mortality rate and PAP level (p<0.046) in the auto-HSCT group. OS was 38% in the pre-auto-HSCT period with PAP values of >25 mmHg, while OS was 61% in the pre-auto-HSCT period with PAP values of <25 mmHg (p<0.001). We determined that there was a statistically significant difference between OS and PAP levels in patients with auto-HSCT. Five-year mortality rate and OS were not significantly different in patients undergoing allogeneic HSCT (allo-HSCT) (p>0.05). Conclusion: Our results suggest that pre-HSCT PAP value is an important risk factor for mortality and OS in patients undergoing auto-HSCT.

show abstract

Section: Discussionmentioning

confidence: 99%